Publications by authors named "Haewook Jang"

Article Synopsis
  • - The effectiveness of treating sepsis heavily relies on quickly giving the right antibiotics; however, current methods for determining the best treatment are slow, primarily due to lengthy blood culture processes.
  • - A new ultra-rapid antimicrobial susceptibility testing (AST) method bypasses traditional blood cultures, potentially speeding up reporting times by 40-60 hours for drug susceptibility profiles.
  • - This innovative approach uses a synthetic peptide to recover a wide range of pathogens from whole blood, achieving 100% species identification accuracy in a study with 190 patients, and a 94.90% agreement rate for AST results within an average of 13 hours after blood processing.
View Article and Find Full Text PDF

A high-throughput, accurate screening is crucial for the prevention and control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Current methods, which involve sampling from the nasopharyngeal (NP) area by medical staffs, constitute a fundamental bottleneck in expanding the testing capacity. To meet the scales required for population-level surveillance, self-collectable specimens can be used; however, its low viral load has hindered its clinical adoption.

View Article and Find Full Text PDF

Since the discovery of antibiotics, the emergence of antibiotic resistance has become a global issue that is threatening society. In the era of antibiotic resistance, finding the proper antibiotics through antibiotic susceptibility testing (AST) is crucial in clinical settings. However, the current clinical process of AST based on the broth microdilution test has limitations on scalability to expand the number of antibiotics that are tested with various concentrations.

View Article and Find Full Text PDF

In addition to SARS-CoV-2 and its variants, emerging viruses that cause respiratory viral infections will continue to arise. Increasing evidence suggests a delayed, possibly suppressed, type 1 interferon (IFN-I) response occurs early during COVID-19 and other viral respiratory infections such as SARS and MERS. These observations prompt considering IFN-β as a prophylactic or early intervention for respiratory viral infections.

View Article and Find Full Text PDF